Advertisement

pp 1-42 | Cite as

Self-Experiments with Psychoactive Substances: A Historical Perspective

  • Torsten PassieEmail author
  • Simon D. Brandt
Chapter
Part of the Handbook of Experimental Pharmacology book series

Abstract

The purpose of this chapter is to highlight the rich tradition of self-experiments (SEs) with psychoactive substances carried out by scientists and therapists for more than a century. Scientifically inspired controlled SEs dominated until the end of the twentieth century, when ethical requirements minimized controlled SEs and “wild” SEs expanded particularly with the emergence of new psychoactive substances. The review focuses on laughing gas (nitrous oxide), cannabis, cocaine, hallucinogens, entactogens, and dissociative hallucinogens. This is due to the fact that substances that induce “complex” effects such as alteration of space/time experience, ego dissolution, and increased feelings and insights (e.g., hallucinogens, entactogens) represent by far the majority of SEs, whereas SEs with substances inducing “simple” effects such as euphoria, anxiolysis, dissociation, or emotional blunting (e.g., cocaine, opioids) are much rarer or even absent (e.g., benzodiazepines). Complex drug effects are much harder to describe, thus allowing SEs to fulfill a more important function.

SEs with psychoactive drugs appeared to emerge in the mid-eighteenth century, which triggered a long-standing tradition throughout the nineteenth and early twentieth century. SEs have been de facto performed for a variety of reasons, ranging from establishing scientific knowledge and gaining philosophical insights to compensating for personal deficits. Self-experimenters can be divided into two general types. Besides their scientific intentions, “exploratory” self-experimenters intend to expand awareness and insight, whereas “compensatory” self-experimenters might aim for coping with psychiatric symptoms or personality deficits. Scientific limitations of SEs are obvious when compared to double-blind, randomized, placebo-controlled trials. Whereas the former might lead to more “realistic” detailed description of subjective effects, the latter lead to more solid results in respect to objectively measurable “average” effects. Possible adverse effects of SEs were identified that resulted in loss of scientific objectivity and decreased control over substance use and addiction, development of isolation, problematic group dynamics, and “social autism.”

Keywords

Cannabis Cocaine Dissociative hallucinogens Entactogens Hallucinogens History of drug use Nitrous oxide Psychoactive substances Self-experiments 

Acronyms of the Discussed Psychoactive Substances

2C-B

2-(4-Bromo-2,5-dimethoxyphenyl)ethan-1-amine

2C-E

2-(4-Ethyl-2,5-dimethoxyphenyl)ethan-1-amine

2C-T-2

2-[4-(Ethylsulfanyl)-2,5-dimethoxyphenyl]ethan-1-amine

2C-T-7

2-[2,5-Dimethoxy-4-(propylsulfanyl)phenyl]ethan-1-amine

2C-T-4

2-[2,5-Dimethoxy-4-(propan-2-ylsulfanyl)phenyl]ethan-1-amine

2C-T-21

2-{4-[(2-Fluoroethyl)sulfanyl]-2,5-dimethoxyphenyl}ethan-1-amine

5-HO-DMT

3-[2-(Dimethylamino)ethyl]-1H-indol-5-ol

AM-2201

[1-(5-Fluoropentyl)-1H-indol-3-yl](naphthalen-1-yl)methanone

LSD

(8β)-N,N-Diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide (d-lysergic acid diethylamide)

MDA

1-(2H-1,3-Benzodioxol-5-yl)propan-2-amine

MDE

1-(2H-1,3-Benzodioxol-5-yl)-N-ethylpropan-2-amine

MDMA

1-(2H-1,3-Benzodioxol-5-yl)-N-methylpropan-2-amine

MEM

1-(4-Ethoxy-2,5-dimethoxyphenyl)propan-2-amine

MPPP

1-Methyl-4-phenylpiperidin-4-yl propanoate

MPTP

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine

References

  1. Abouchedid R, Gilks T, Dargan PI, Archer JRH, Wood DM (2018) Assessment of the availability, cost, and motivations for use over time of the new psychoactive substances-benzodiazepines diclazepam, flubromazepam, and pyrazolam-in the UK. J Med Toxicol 14:134–143Google Scholar
  2. Abramson HA (ed) (1967) The use of LSD in psychotherapy and alcoholism. Bobbs-Merrill, IndianapolisGoogle Scholar
  3. Alberts L (1921) Einwirkungen des Meskalins auf komplizierte psychische Vorgänge. Dissertation, Heidelberg University, HeidelbergGoogle Scholar
  4. Alles G (1959) Subjective reactions to phenethylamine hallucinogens. In: Featherstone RM, Simon A (eds) A pharmacologic approach to the study of the mind. C.C. Thomas, Springfield, pp 238–250Google Scholar
  5. Altman LK (1972) Auto-experimentation – an unappreciated tradition in medical science. N Eng J Med 286:346–352Google Scholar
  6. Altman LK (1986) Who goes first? The story of self-experimentation in medicine. Random House, New YorkGoogle Scholar
  7. Ameline A, Richeval C, Gaulier JM, Raul JS, Kintz P (2018) Characterization of flunitrazolam, a new designer benzodiazepine, in oral fluid after a controlled single administration. J Anal Toxicol 42:e58–e60Google Scholar
  8. Ammon G, Patterson PGR (1971) Peyote: Zwei verschiedene Ich-Erfahrungen. Dyn Psychiatr 4(Supplement 1):47–71Google Scholar
  9. Anderson GM, Braun G, Braun U, Nichols DE, Shulgin AT (1978) Absolute configuration and psychotomimetic activity. In: Barnett G, Trsic M, Willette R (eds) QuaSAR – quantitative structure–activity relationships. NIDA research monograph, vol 22. United States Department of Health, Education, and Welfare, Washington, pp 8–15Google Scholar
  10. Arnold OH, Hoff H (1953) Untersuchungen über die Wirkungsweise von Lysergsäurediäthylamid. Wien Z Nervenheilkd Grenzgeb 6:129–150Google Scholar
  11. Arthur JD (2008) Peopled darkness: perceptual transformation through Salvia divinorum. iUniverse, New YorkGoogle Scholar
  12. Assi S, Gulyamova N, Kneller P, Osselton D (2017) The effects and toxicity of cathinones from the users’ perspectives: a qualitative study. Hum Psychopharmacol 32:e2610Google Scholar
  13. Auwärter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N (2009) ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832–837Google Scholar
  14. Baumann MH, Glennon RA, Wiley JL (2017) Neuropharmacology of new psychoactive substances (NPS). In: The science behind the headlines. Springer, ChamGoogle Scholar
  15. Becker AM (1949) Zur Psychopathologie der Lysergsäurediäthylamidwirkung. Wiener Z Nervenhk 2:402–407Google Scholar
  16. Beecher HK (1959) Experimentation in man. J Am Med Assoc 169:461–478Google Scholar
  17. Benz E (1989) Halluzinogen-unterstützte Psychotherapie. Medical dissertation, University of Zürich, ZürichGoogle Scholar
  18. Benzenhöfer U, Passie T (2010) Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin. Addiction 105:1355–1361Google Scholar
  19. Beringer K (1923) Experimentelle Psychosen durch Mescalin. Z ges Neurol Psychiatr 84:426–433Google Scholar
  20. Beringer K (1927) Der Meskalinrausch. Springer, BerlinGoogle Scholar
  21. Beringer K (1932) Zur Klinik des Haschischrausches. Nervenarzt 5:337–342Google Scholar
  22. Bisbort A (2009) Beatniks: a guide to an American subculture. Greenwood, WestportGoogle Scholar
  23. Brandt SD, King LA, Evans-Brown M (2014) The new drug phenomenon. Drug Test Anal 6:587–597Google Scholar
  24. Bumke O (1903) Scopolaminum hydrobromicum. Monatsschr Psychiatr Neurol 13:62–69Google Scholar
  25. Caldwell WV (1968) LSD psychotherapy: an exploration of psychedelic and psycholytic therapy. Grove Press, New YorkGoogle Scholar
  26. Calton T, Ferriter M, Huband N, Spandler H (2008) A systematic review of the Soteria paradigm for the treatment of people diagnosed with schizophrenia. Schizophr Bull 34:181–192Google Scholar
  27. Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3:619–627Google Scholar
  28. Castiglioni A (1947) A history of medicine. Alfred A. Knopf, New YorkGoogle Scholar
  29. Cohen S (1964) The beyond within the L.S.D. story. Atheneum, New York, pp 106–111Google Scholar
  30. Cohen S (1967) Discussion. In: Abramson HA (ed) The use of LSD in psychotherapy. Josiah Macy, New York, p 11Google Scholar
  31. Condrau G (1949) Klinische Erfahrungen an Geisteskranken mit Lysergsäure-Diäthylamid. Acta Psychiatr Scand 24:9–32Google Scholar
  32. Crowley A ([1917] 1973) Cocaine. Level Press, San FranciscoGoogle Scholar
  33. Dargan PI, Wood DM (eds) (2013) Novel psychoactive substances. Academic Press, AmsterdamGoogle Scholar
  34. Davy H (1800) Researches, chemical and philosophical: chiefly concerning nitrous oxide, or diphlogisticated nitrous air, and its respiration. J. Johnson, LondonGoogle Scholar
  35. Downing JJ (1965) Zihuatanejo: an experience of transpersonative living. In: Blum R (ed) Utopiates – the use and users of LSD. Tavistock Publications, London, pp 142–178Google Scholar
  36. Dulchinos DP (1999) Fitz Hugh Ludlow: pioneer of inner space. In: Lyttle T (ed) Psychedelics reimagined. Autonomedia, New York, pp 29–40Google Scholar
  37. Ellis H (1898) Mescal, a new artificial paradise. Contemp Theatr Rev 73:131–141Google Scholar
  38. Erowid E, Erowid F (2015) The kratom experience from firsthand reports. In: Raffa RB (ed) The chemistry and pharmacology of opioids from a non-opium source. CRC Press, Boca Raton, pp 213–244Google Scholar
  39. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2015) New psychoactive substances in Europe. An update from the EU early warning system. http://www.emcdda.europa.eu/system/files/publications/65/TD0415135ENN.pdf. Accessed 1 May 2018
  40. Evans-Brown M, Sedefov R (2018) Responding to new psychoactive substances in the European Union: early warning, risk assessment, and control measures. Handb Exp Pharmacol.  https://doi.org/10.1007/164_2018_160Google Scholar
  41. Feldman HW, Agar MH, Beschner GM (eds) (1979) Angel dust. An ethnographic study of phencyclidine users. Lexington Books, LexingtonGoogle Scholar
  42. Ferkel S (1954) “Hexensalben” und ihre Wirkung. Kosmos 50:414–415Google Scholar
  43. Fischer R (1946) Selbstbeobachtungen im Meskalinrausch. Schweiz Z Psychol 5:308–313Google Scholar
  44. Fränkel F, Joël E (1927) Beiträge zu einer experimentellen Psychopathologie: der Haschischrausch. Z ges Neurol Psychiatr 111:84–106Google Scholar
  45. Frederking W (1955) Intoxicant drugs (mescaline and lysergic acid diethylamide) in psychotherapy. J Nerv Ment Dis 121:262–266Google Scholar
  46. Freud S (1884) Über Coca. Centralbl ges Ther 2:289–314Google Scholar
  47. Freud S (1885a) Beitrag zur Kenntnis der Coca-Wirkung. Wien Med Wochenschr 5:129–133Google Scholar
  48. Freud S (1885b) Zur Coca-Wirkung beim gesunden Menschen. Centralbl ges Ther 3:253–254Google Scholar
  49. Friedrichs H ([1940] 2009) Die Psychologie des Meskalinrausches. VWB, BerlinGoogle Scholar
  50. Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202:513–520Google Scholar
  51. Gonzalez D, Riba J, Bouso JC, Gomez-Jarabo G, Barbanoj MJ (2006) Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend 85:157–162Google Scholar
  52. Grof S (1964) K problematice optických poruch v autoexperimentech s halucinogeny. Česk Psychiatr 3:173–181Google Scholar
  53. Grof S (1980) LSD psychotherapy. Hunter House, PomonaGoogle Scholar
  54. Guttmann (1921) Hallluzinationen und andere Folgeerscheinungen nach experimenteller Vergiftung mit Anhalonium (Mescal). Berl Klin Wochenschr 58:816–817Google Scholar
  55. Haldane JS (1922) Respiration. Yale University Press, New HavenGoogle Scholar
  56. Haldane JS, Smith JL (1893) The physiological effects of air ventilated by respiration. J Pathol Bacteriol 1:168–186Google Scholar
  57. Hearne E, Van Hout MC (2016) “Trip-sitting” in the black hole: a netnographic study of dissociation and indigenous harm reduction. J Psychoactive Drugs 48:233–242Google Scholar
  58. Heffter A (1894) Über Pellote. Arch Exp Pathol Pharmakol 34:65–86Google Scholar
  59. Heffter A (1898) Über Pellote. Zweite Mitteilung. Arch Exp Pathol Pharmakol 40:385–429Google Scholar
  60. Heimann H (1952) Die Scopolaminwirkung. Karger, BaselGoogle Scholar
  61. Henderson GL (1988) Designer drugs: past history and future prospects. J Forensic Sci 33:569–575Google Scholar
  62. Henderson L, Glass W (eds) (1994) LSD: still with us after all these years. Lexington Books, New YorkGoogle Scholar
  63. Hoffer A, Osmond H (1967) The hallucinogens. Academic Press, New YorkGoogle Scholar
  64. Hofmann A (1955) The history of LSD-25. Triangle 2:117–124Google Scholar
  65. Hofmann (1979) LSD-mein Sorgenkind. Klett-Cotta, StuttgartGoogle Scholar
  66. Hollingshead M (1973) The man who turned on the world. Blond & Briggs, LondonGoogle Scholar
  67. Huppertz LM, Moosmann B, Auwärter V (2018) Flubromazolam – basic pharmacokinetic evaluation of a highly potent designer benzodiazepine. Drug Test Anal 10:206–211Google Scholar
  68. Hutter M, Moosmann B, Kneisel S, Auwärter V (2013) Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM-2201 regarding its chemistry and metabolism. J Mass Spectrom 48:885–894Google Scholar
  69. Huxley A (1954) The doors of perception. Chatto & Windus, LondonGoogle Scholar
  70. Huxley A (1980) Moksha. Chatto & Windus, LondonGoogle Scholar
  71. James W (1882) Subjective effects of nitrous oxide. Mind 7:186–208Google Scholar
  72. James W (1902) The varieties of religious experience. Longmans, New YorkGoogle Scholar
  73. Jansen KL (2000) A review of the nonmedical use of ketamine: use, users and consequences. J Psychoactive Drugs 32:419–433Google Scholar
  74. Jansen K ([2001] 2004) Ketamine: dreams and realities. MAPS, SarasotaGoogle Scholar
  75. Jansen KL, Darracot-Cankovic R (2001) The nonmedical use of ketamine, part two: a review of problem use and dependence. J Psychoactive Drugs 33:151–158Google Scholar
  76. Jay M (2009) The atmosphere of heaven. Yale University Press, LondonGoogle Scholar
  77. Jöel E, Fränkel F (1924) Der Cocainismus. Ein Beitrag zur Geschichte und Psychopathologie der Rauschgifte. Springer, BerlinGoogle Scholar
  78. Jöel E, Fränkel F (1926) Der Haschisch-Rausch. Beiträge zu einer experimentellen Psychopathologie. Klin Wochenschr 5:1707–1709Google Scholar
  79. Joël E, Fränkel F (1929) Beiträge zur experimentellen Psychopathologie. Klin Wochenschr 8:549–550Google Scholar
  80. Kant F, Kropf E (1928) Über Selbstversuche mit Haschisch. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 129:319–338Google Scholar
  81. Kelly K (1999) The little book of ketamine. Ronin, BerkeleyGoogle Scholar
  82. Ketchum J (2006) Chemical warfare secrets almost forgotten. Chembooks, Santa RosaGoogle Scholar
  83. King LA (2014) New phenethylamines in Europe. Drug Test Anal 6:808–818Google Scholar
  84. King LA, Kicman AT (2011) A brief history of ‘new psychoactive substances’. Drug Test Anal 3:401–403Google Scholar
  85. Kintz P, Richeval C, Jamey C, Ameline A, Allorge D, Gaulier JM, Raul JS (2017) Detection of the designer benzodiazepine metizolam in urine and preliminary data on its metabolism. Drug Test Anal 9:1026–1033Google Scholar
  86. Kirsch MM (1986) Designer drugs. CompCare Publications, MinneapolisGoogle Scholar
  87. Kjellgren A, Jonsson K (2013) Methoxetamine (MXE) – a phenomenological study of experiences induced by a “legal high” from the internet. J Psychoactive Drugs 45:276–286Google Scholar
  88. Kjellgren A, Soussan C (2011) Heaven and hell – a phenomenological study of recreational use of 4-HO-MET in Sweden. J Psychoactive Drugs 43:211–219Google Scholar
  89. Kjellgren A, Henningsson H, Soussan C (2013) Fascination and social togetherness-discussions about spice smoking on a Swedish internet forum. Subst Abuse 7:191–198Google Scholar
  90. Klinke O (1889) Hyoscin bei Geisteskranken. Z Nervenheilkd Psychopathol 12:189–196Google Scholar
  91. Klüver H (1966) Mescal and mechanisms of hallucinations. University of Chicago Press, ChicagoGoogle Scholar
  92. Klüver H (1980) Foreword. In: Schultes RE, Hofmann A (eds) The botany and chemistry of hallucinogens, 2nd edn. C.C. Thomas, Springflied, pp VII–VVXGoogle Scholar
  93. Knauer A, Maloney WJ (1913) A preliminary note on the psychic action of mescaline, with special reference to the mechanism of visual hallucinations. J Nerv Ment Dis 40:425–436Google Scholar
  94. Konrad E (1888) Zur physiologischen und therapeutischen Wirkung des Hyoscinum hydrochloricum. Centralbl Nervenheilk 11:529Google Scholar
  95. Langston JW (2017) The MPTP story. J Parkinsons Dis 7:S11–S22Google Scholar
  96. Leary T (1966) Programmed communication during experiences with DMT (dimethyltryptamine). Psychedelic Rev 8:83–95Google Scholar
  97. Leary T, Litwin GH, Metzner R (1963) Reactions to psilocybin administered in a supportive environment. J Nerv Ment Dis 137:561–573Google Scholar
  98. Lewin L (1924) Phantastica. Die betäubenden und erregenden Genussmittel. Für Ärzte und Nichtärzte. Verlag von Georg Stilke, BerlinGoogle Scholar
  99. Lewin L (1888) Über Anhalonium lewinii. Arch Exp Pathol Pharmakol 24:401–411Google Scholar
  100. Lewin L (1998) Phantastica: a classic survey on the use and abuse of mind-altering plants. Park Street Press, RochesterGoogle Scholar
  101. Lilly JC (1972a) Programming and metaprogramming in the human biocomputer. Julian Press, New YorkGoogle Scholar
  102. Lilly JC (1972b) The center of the cyclone. Julian Press, New YorkGoogle Scholar
  103. Lilly JC (1978) The scientist. Crown Publishers, New YorkGoogle Scholar
  104. Ludlow F (1857) The Hasheesh eater. Harper & Bros, New YorkGoogle Scholar
  105. Mantegazza P (1859 [1973]) Sulle virtu igienische e medicale de la coca. Ann univers di medic Bd. 167:449ff. Partially reprinted. In: Andrews G, Solomon D (eds) The coca leaf and cocaine papers. Harcourt Brace Jovanovich, New York, pp 38–42Google Scholar
  106. Maqueda AE, Valle M, Addy PH, Antonijoan RM, Puntes M, Coimbra J, Ballester MR, Garrido M, Gonzalez M, Claramunt J, Barker S, Johnson MW, Griffiths RR, Riba J (2015) Salvinorin-A induces intense dissociative effects, blocking external sensory perception and modulating interoception and sense of body ownership in humans. Int J Neuropsychopharmacol 18:pyv065Google Scholar
  107. Matussek N (1952) Wahnsymptome im Meskalinrausch. Medical dissertation, Max-Planck-Institut für Psychiatrie, MünchenGoogle Scholar
  108. Mayer-Gross W, McAdam W, Walker JW (1951) Psychological and biochemical effects of lysergic acid diethylamide. Nature 168:827–828Google Scholar
  109. McGlothlin W, Cohen S, McGlothlin MS (1967) Long lasting effects of LSD on normals. Arch Gen Psychiatry 17:521–532Google Scholar
  110. McKenna T (1991) The archaic revival. Speculations on psychedelic mushrooms, the amazon, virtual reality, UFOs, evolution, shamanism, the rebirth of the goddess, and the end of history. Harper Collins, San FranciscoGoogle Scholar
  111. Meyer P (1993) Apparent communication with discarnate entities related to DMT. Psychedelic Monogr Essays 6:29–67Google Scholar
  112. Meyer MR (2018) Toxicokinetics of NPS: update 2017. Handb Exp Pharmacol.  https://doi.org/10.1007/1164_2018_1102
  113. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R (2011) The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 25:439–452Google Scholar
  114. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Martin SF, Yazar-Klosinski B, Michel Y, Brewerton TD, Doblin R (2013) Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol 27:28–39Google Scholar
  115. Mithoefer MC, Mithoefer AT, Feduccia AA, Jerome L, Wagner M, Wymer J, Holland J, Hamilton S, Yazar-Klosinski B, Emerson A, Doblin R (2018) 3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry 5:486–497Google Scholar
  116. Moore M, Alltounian HS (1978) Journeys into the bright world. Para Research, RockportGoogle Scholar
  117. Moosmann B, Huppertz Laura M, Hutter M, Buchwald A, Ferlaino S, Auwärter V (2013a) Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics. J Mass Spectrom 48:1150–1159Google Scholar
  118. Moosmann B, Hutter M, Huppertz LM, Ferlaino S, Redlingshöfer L, Auwärter V (2013b) Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine. Forensic Toxicol 31:263–271Google Scholar
  119. Moosmann B, Bisel P, Auwärter V (2014) Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics. Drug Test Anal 6:757–763Google Scholar
  120. Morris H, Wallach J (2014) From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Test Anal 6:614–632Google Scholar
  121. Mosher L (1999) Lecture on Soteria treatment for psychotic patients. Hannover Medical School, HannoverGoogle Scholar
  122. Nichols DE (2016) Psychedelics. Pharmacol Rev 68:264–355Google Scholar
  123. Novak SJ (1997) LSD before Leary. Sidney Cohen’s critique of 1950s psychedelic drug research. Isis 88:87–110Google Scholar
  124. Osmond H (1970) Peyote night. In: Aaronson BS, Osmond H (eds) Psychedelics. The Hogarth Press, London, pp 67–86Google Scholar
  125. Oss OT, Oeric ON (1976) Psilocybin – magic mushroom grower’s guide. And/Or Press, BerkeleyGoogle Scholar
  126. Ott J (1994) Ayahuasca analogues–Pangean entheogens. Natural Products, WashingtonGoogle Scholar
  127. Ott J (1999) Pharmahuasca: human pharmacology of oral DMT plus harmine. J Psychoactive Drugs 31:171–177Google Scholar
  128. Ott J (2001a) Shamanic snuffs or entheogenic errhines. Entheobotanica, SolothurnGoogle Scholar
  129. Ott J (2001b) Pharmañopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine. J Psychoactive Drugs 33:273–281Google Scholar
  130. Ott J (2001c) Pharmepéna-psychonautics: human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine. J Psychoactive Drugs 33:403–407Google Scholar
  131. Passie T (1997) Hanscarl Leuner: pioneer of hallucinogen research and psycholytic therapy. Multidiscipl Assoc Psychedelic Stud Bull 7:46–49Google Scholar
  132. Passie T (2002) Protocol for a research study of psilocybin in a clinical setting. Hannover Medical School, HannoverGoogle Scholar
  133. Passie T (2005) Meskalin in Deutschland 1912–1945: Grundlagenforschung, Selbstversuche und Missbrauch. In: Pieper W (ed) Nazis on speed, vol 2, pp 234–244Google Scholar
  134. Passie T (2018) The early use of MDMA (‘Ecstasy’) in psychotherapy (1977–1985). Drug Sci Policy Law 4:1–19Google Scholar
  135. Passie T, Benzenhöfer U (2016) The history of MDMA as an underground drug in the United States, 1960–1979. J Psychoactive Drugs 48:67–75Google Scholar
  136. Passie T, Benzenhöfer U (2018) MDA, MDMA and other “mescaline-like” substances in the US military’s search for a truth drug (1940s to 1960s). Drug Test Anal 10:72–80Google Scholar
  137. Pickering GW (1949) The place of experimental method in medicine. Proc R Soc Med 42:229–234Google Scholar
  138. Prentiss DW, Morgan FP (1895) Anhalonium lewinii (Mescal buttons): a study of the drug with special reference to its physiological action upon man with report of experiments. Therapeut Gaz 19:577–585Google Scholar
  139. Prinzhorn H (1927) Erdentrückte Seele. Leuchter 8:277–296Google Scholar
  140. Prinzhorn H (1928) Entrückung durch Rauschgift. Zeitsch Parapsychol 55:24–34Google Scholar
  141. Resnikoff C (2018) Mail to Torsten Passie. 6 Apr 2018Google Scholar
  142. Ring FW (1887) Cocaine and its fascinations, from a personal experience. Medical Record, September 3, 1887. In: Andrews G, Solomon D (eds) The coca leaf and cocaine papers, vol 1973. Harcourt Brace Jovanovich, New York, pp 253–258Google Scholar
  143. Roubíček J (1961) Experimentální psychosy. SZdN, PragueGoogle Scholar
  144. Shedlin M, Wallechinski D, Sayler S (eds) ([1973] 1992) Laughing gas. Ronin, BerkeleyGoogle Scholar
  145. Shulgin AT (1975) Centrally active phenethylamines. Psychopharmacol Commun 1:93–98Google Scholar
  146. Shulgin A, Shulgin A (1991) PIHKAL. Transform Press, BerkeleyGoogle Scholar
  147. Shulgin A, Shulgin A (1997) TIHKAL. Transform Press, BerkeleyGoogle Scholar
  148. Shulgin AT, Shulgin LA, Jacob PA (1986) A protocol for the evaluation of new psychoactive drugs. Methods Find Exp Clin Pharmacol 8:313–320Google Scholar
  149. Siebert DJ (1994) Salvia divinorum and Salvinorin A – new pharmacological findings. J Ethnopharmacol 43:53–56Google Scholar
  150. Simpson ESC, Weiner JA (eds) (1989) The Oxford encyclopaedic English dictionary. Clarendon Press, OxfordGoogle Scholar
  151. Solms H (1956) Relationships between chemical structure and psychoses with the use of psychotoxic substances. “Comparative pharmacopsychiatric analysis”: a new research method. J Clin Exp Psychopathol 17:429–433Google Scholar
  152. Solomon D (1964) Editor’s preface. In: Solomon D (ed) LSD – the consciousness-expanding drug. Putnam’s, New York, pp IX–IXGoogle Scholar
  153. Soussan C, Kjellgren A (2014) Harm reduction and knowledge exchange – a qualitative analysis of drug-related internet discussion forums. Harm Red J 11:25–33Google Scholar
  154. Soussan C, Kjellgren A (2015) “Chasing the high” – experiences of ethylphenidate as described on international internet forums. Subst Abuse 9:9–16Google Scholar
  155. Soussan C, Andersson M, Kjellgren A (2018) The diverse reasons for using novel psychoactive substances – a qualitative study of the users’ own perspectives. Int J Drug Policy 52:71–78Google Scholar
  156. Stafford P (1990) Magic grams: investigations into psychedelic consciousness with Dr. Oscar Janiger. Psychedelic Monogr Essays 5Google Scholar
  157. Stolaroff M (1994) Thanatos to Eros: thirty-five years of psychedelic exploration. VWB, BerlinGoogle Scholar
  158. Stolaroff M (2004) The secret chief revealed. MAPS, SarasotaGoogle Scholar
  159. Stoll WA (1947) Lysergsäure-diäthylamid, ein Phantastikum aus der Mutterkorngruppe. Schweiz Arch Neurol Psychiat 60:279–280Google Scholar
  160. Styk J (1994) Rückblick auf die letzten sieben Jahre der Schweizerischen Ärztegesellschaft für Psycholytische Therapie (SÄPT). In: Dittrich A, Hofmann A, Leuner H (eds) Welten des Bewusstseins, vol 4. VWB, Berlin, pp 149–154Google Scholar
  161. Swogger MT, Hart E, Erowid F, Erowid E, Trabold N, Yee K, Parkhurst KA, Priddy BM, Walsh Z (2015) Experiences of Kratom users: a qualitative analysis. J Psychoactive Drugs 47:360–367Google Scholar
  162. Szára S (1957) The comparison of the psychotic effect of tryptamine derivatives with the effects of mescaline and LSD-25 in self-experiments. In: Garattini S, Ghetti V (eds) Psychotropic drugs. Elsevier, Amsterdam, pp 460–467Google Scholar
  163. Szára S (1961) Hallucinogenic effects and metabolism of tryptamine derivatives in man. Fed Proc 20:885–888Google Scholar
  164. Tettey JNA, Crean C, Ifeagwu SC, Raithelhuber M (2018) Emergence, diversity and control of new psychoactive substances – a global perspective. Handb Exp Pharmacol.  https://doi.org/10.1007/164_2018_XXX
  165. Trachsel D (2011) Psychedelische chemie. Nachtschatten Verlag, SolothurnGoogle Scholar
  166. Trachsel D (2012) Fluorine in psychedelic phenethylamines. Drug Test Anal 4:577–590Google Scholar
  167. Trachsel D, Lehmann D, Enzensperger C (2013) Phenethylamine: Von der Struktur zur Funktion. Nachtschatten Verlag, SolothurnGoogle Scholar
  168. Turner DM (1996) Salvinorin – the psychedelic essence of Salvia divinorum. Panther Press, San FranciscoGoogle Scholar
  169. United Nations Office on Drugs and Crime (UNODC) (2018) Understanding the synthetic drug market: the NPS factor. https://www.unodc.org/documents/scientific/Global_Smart_Update_2018_Vol.19.pdf. Accessed 29 May 2018
  170. Valdes LJ, Diaz JL, Paul AG (1982) Ethnopharmacology of Ska Maria Pastora (Salvia divinorum Epling and Jativa-M.). J Ethnopharmacol 7:287–312Google Scholar
  171. Van Dusen W (1961) LSD and the enlightenment of Zen. Psychologia 4:11–16Google Scholar
  172. Van Hout MC (2014) An internet study of user’s experiences of the synthetic cathinone 4-methylethcathinone (4-MEC). J Psychoactive Drugs 46:273–286Google Scholar
  173. Van Hout MC, Hearne E (2015a) “Plant or poison”: a netnographic study of recreational use of 1,3-dimethylamylamine (DMAA). Int J Drug Policy 26:1279–1281Google Scholar
  174. Van Hout MC, Hearne E (2015b) “Word of mouse”: indigenous harm reduction and online consumerism of the synthetic compound methoxphenidine. J Psychoactive Drugs 47:30–41Google Scholar
  175. Wagmann L, Maurer HH (2018) Bioanalytical methods for new psychoactive substances. Handb Exp Pharmacol.  https://doi.org/10.1007/1164_2017_1083
  176. Waser PG (1990) Psychiatrie, psychopharmaka und drogen in Zürich. Kommissionsverlag Beer AG, ZürichGoogle Scholar
  177. Wasson RG (1962) Salvia divinorum – a new psychotropic drug from the mint family. Bot Mus Leafl Harvard Univ 20:77–84Google Scholar
  178. Weil A (1976) MDA – the love drug. J Psychedelic Drugs 8:335–337Google Scholar
  179. Weil A (1980) The marriage of the sun and the moon. Houghton Mifflin, BostonGoogle Scholar
  180. Weir Mitchell S (1896) Remarks on the effects of Anhelonium lewinii (the mescal button). Br Med J 2:1625–1629Google Scholar
  181. Wellen BJ (1986) Zur Geschichte des Bilsenkrautes. Dissertation, Fachbereich Pharmazie Philipps-Universität Marburg, MarburgGoogle Scholar
  182. Weyl B (1951) Versuch einer psychopathologischen analyse der LSD-Wirkung. Medical dissertation, Albert-Ludwig-University Freiburg, Freiburg im BreisgauGoogle Scholar
  183. Widmer S (1997) Ins Herz der Dinge Lauschen, 2nd edn. Nachtschatten, SolothurnGoogle Scholar
  184. Winkler P, Csémy L (2014) Self-experimentations with psychedelics among mental health professionals: LSD in the former Czechoslovakia. J Psychoactive Drugs 46:11–19Google Scholar
  185. Wood HC Jr (1869) On the medical activity of the hemp plant as grown in North America. Proc Am Philos Soc 11:226–232Google Scholar
  186. Zucker K (1926) Die pharmakologische Betrachtungsweise als Forschungsmethode in der Neurologie und Psychiatrie. Klin Wochenschr 5:1977–1779Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Senckenberg Institute for History and Ethics in Medicine, Goethe-University Frankfurt/MainFrankfurtGermany
  2. 2.School of Pharmacy and Biomolecular SciencesLiverpool John Moores UniversityLiverpoolUK

Personalised recommendations